Kornimate/medical-research-clean huggingface dataset:
compare the healing process of idiopathic macular hole with different surgical techniques

Conditions: Macular Holes

Summary: to compare anatomic and functional results, and to evaluate postoperatively the healing process in 2 different techniques for the closure of the macular holes (mh)

patients with macular holes classified in stages 3 and 4 will be randomized into 2 groups. . in group a, patients will undergo peeling with complete removal of the internal limiting membrane (ilm) and in the group b, the inverted ilm peeling technique will be performed. the 20% sulfur hexafluoride (sf6) gas will be used as a tamponade agent in all surgeries, and patients will be instructed to avoid the prone position for 5 days. oct images will be performed in the first 5 postoperative days and months 1, 3 and 6. the primary outcome is anatomic closure of the mh closure in the month 6. the second outcomes are: mean best corrected visual acuity (bcva) at month 6, mean change in the bcva at month 6; integrity of the perifoveal external limiting membrane and ellipsoid zone on optical coherence tomography (oct); mh closure rate over time in days; functional improvement of microperimetry statistical analysis will be performed with student t-test and the p-value of ≤ 0.05 is considered significant.

Eligibility criteria:
inclusion criteria: \> stage 3 and 4 macular holes with visual acuity between 20/30 and 20/800 according to the etdrs chart. exclusion criteria: * macular holes secondary to ocular trauma, myopia or retinal detachment * any previous treatment for the macular hole * evidence on examination of any diabetic retinopathy * history or presence of wet or dry age macular degeneration (amd) * presence of epiretinal membrane or prior uveitis * any ocular surgery within 3 months before baseline * intra or periocular infection

Keywords: macular holes
the pathophysiology of the onset of atrial fibrillation in obstructive sleep apnea

Conditions: Atrial Fibrillation; Obstructive Sleep Apnea of Adult

Summary: rationale: obstructive sleep apnea (osa) is a highly prevalent, often undiagnosed, modifiable risk factor for atrial fibrillation (af), as well as af-related complications and treatment effectiveness. it is unclear which osa-related pathophysiological mechanism, i.e. intrathoracic pressure shifts, hypoxemia or sympathovagal imbalance, plays the most dominant role, and a better understanding of these mechanisms could provide valuable information in future diagnostic and therapeutic strategies in this population. objective: the primary objective is to assess the role of osa-related pathophysiological mechanisms in the initiation of af by a multi-parametric strategy that combines the estimated parameters. the main hypothesis is that intrathoracic pressure fluctuations are the predominant mechanism. the secondary objective is to validate a nonobtrusive sensing technology based on photoplethysmography (ppg) and diaphragm electromyography (demg) measurements as surrogates for gold standard technology based on invasive intraoesophageal pressure (pes) measurement. study population: adult patients with paroxysmal af with nocturnal onset and high risk of osa based on the stop-bang questionnaire. study design: an observational study in a selected cohort. subjects are recruited from the af outpatient clinic of the catharina hospital, and referred to kempenhaeghe centre for sleep medicine for a one-night full psg, with the addition of demg and ppg. the acquired data will be analysed at the eindhoven technical university. main study parameters/endpoints: primary endpoint: identification of prognostic factors for the initiation of af in relation to osa-related pathophysiological mechanisms..nl


Eligibility criteria:
inclusion criteria: paroxysmal or persistent af and * stop-bang score \>5 or stop-bang \>4 and typical nocturnal onset of af * a positive watch-pat screening * very high clinical suspicion of osa, with stop-bang score \>3 exclusion criteria: * current adequate treatment of osa * reversible cause of af * severe lung disease (copd gold iv, pumonary fibrosis, lobectomy) wever esophageal disease (malignancy, stricture, esophagectomy)
influence of moderate inspired oxygen fraction (fio2) and protective ventilation on postoperative pulmonary complication

Conditions: Hepatectomy

Summary: the purpose of this study is to determine the influence of moderate fio2 and the lung protective ventilation on postoperative pulmonary complications following hepatic resection surgery.


Eligibility criteria:
inclusion criteria: * asa 1\~2,planned intrabdominal hepatic resection surgery; * expected duration 2 hours to 6 hours; * age 40 yr to 70 yr); * bmi 18-26.9kg/m2 * risk of postoperative pulmonary complications (arozullah score ≥2); exclusion criteria: * noninvasive ventilation in the last 30 days; * recent history of pneumonia, ali/ards (in the last 30 days); * history of pulmonary resection; * history of neuromuscular disease; * child-pugh\>a grade； * patient refusal;

Keywords: moderate fio2 protective lung ventilation postoperative pulmonary complications positive end-expiratory pressure recruitment maneuvers
nasal obstruction in sleep apnea patients compared to the general population

Conditions: Obstructive Sleep Apnoea Syndrome; Nasal Obstruction

Summary: recent clinical findings of research at trondheim university hospital suggest that surgical correction of the nose septum in addition to volume reduction of the nose cavity may be beneficial in patients who suffer from both nose obstruction and obstructive sleep apnea syndrome(data not yet published). this study aims to compare nose obstruction prevalence in sleep apnea patients and the general population


Eligibility criteria:
inclusion criteria: * ??? exclusion criteria: * ???

Keywords: general population prevalence norway
breathwork-assisted treatment for cannabis use disorder

Conditions: Addiction; Substance Abuse; Cannabis Use Disorder; Cannabis Use; Cannabis Dependence; Cannabis Abuse

Summary: the purpose of this proof-of-concept study is to evaluate the safety, feasibility and acceptability of a breathwork workshop intervention in individuals with cannabis use disorder.

this study will test a 1-week breathwork workshop for treatment-seeking adults with a diagnosis of cannabis use disorder. the intervention consists of an enhanced breathing session with evocative music to facilitate experiencing non-ordinary states of consciousness, in addition to brief therapeutic interventions based on motivational interviewing and mindfulness-based relapse prevention (mbrp). the primary aim is to test the acceptability, feasibility and safety of enhanced breathwork in a therapeutic framework for cannabis use disorder. in addition, the investigators seek to understand the phenomenology of breathwork that may explain any change related to addictive behaviors, as well as biological changes that occur during the breathwork session through heart rate variability and electroencephalography.

Eligibility criteria:
inclusion criteria: * 18-70 years of age * meets diagnostic and statistical manual of mental disorders, fifth edition (dsm-v) criteria for active cannabis use disorder. * seeking treatment for their cannabis use exclusion criteria: * meets dsm-v criteria for schizophrenia or any psychotic illness or any dissociative disorder (dissociative identity disorder, dissociative amnesia, depersonalization/derealization disorder). * active substance use disorder except for cannabis, nicotine, and caffeine. * history of severe withdrawal symptoms (i.e withdrawal seizures). * history of dementia, epilepsy or seizures, cardiac arrhythmia, pacemaker/defibrillator, heart failure, asthma, panic disorder and other respiratory illnesses (ie: copd).

Keywords: addiction cannabis use disorder breathwork non-ordinary states of consciousness non-ordinary experiences contemplative practices altered states of consciousness cannabis
evaluation of the juice ha® as an anti-sarcopenia

Conditions: Sarcopenia in Elderly

Summary: this study plans to recruit 60 participants aged 65 years and older who have been diagnosed with sarcopenia by a physician. participants will be randomly assigned into juice ha® supplement and placebo group. all of the participants will be asked to take 15 ml/day of juice ha® supplement or placebo group for 12 weeks. the aim of this trial is to evaluate the potential of juice ha® to enhance physiological status (muscle mass and functional fitness) and to improve the quality of life in patients with sarcopenia.

juice ha® is a nutritional supplement formulated with hyaluronic acid (ha), branched-chain amino acids (bcaa), and chondroitin. hyaluronic acid contributes to enhancing hydration levels in the skin and connective tissues; bcaa promotes muscle protein synthesis and repair; and chondroitin is believed to support the structural integrity and functionality of joints. the synergistic combination of these components is anticipated to provide comprehensive, multidimensional support for individuals with sarcopenia, potentially alleviating symptoms and improving overall quality of life. therefore, this study will explore 15 ml/day of juice ha® supplement to improve the muscle mass and functional fitness in the elderly with sarcopenia. this study aims to recruit 60 participants aged 65 years and older who have been diagnosed with sarcopenia by a physician and meet the asian working group for sarcopenia (awgs) 2019 diagnostic criteria. participants will be enrolled in a randomized control-group pretest-posttest design and randomly assigned to receive either the juice ha® supplement or a placebo (lin et al., 2021). functional fitness assessments, the sarcopenia quality of life questionnaire (sarqol), and blood sample collections will be conducted at baseline, at the 6th and 12th weeks of the supplementation period, and at the 6th and 12th weeks of the follow-up period. blood samples will be analyzed for oxidative stress markers (sod, mda), inflammatory markers (tnf-α, il-10), and muscle synthesis and degradation indicators (mtor, murf1, atrogin-1). body composition assessments will be performed at baseline, at the 12th week of the supplementation period, and at the 12th week of the follow-up period.

Eligibility criteria:
inclusion criteria: * participants that have been diagnosed with sarcopenia by a physician and meet the awgs 2019 criteria for sarcopenia. exclusion criteria: * participants with a history of severe lower extremity musculoskeletal injuries within the past six months or those who have a fear of blood sampling will be excluded.

Keywords: sarcopenia quality of life
low vs standard pneumoperitoneum pressure during single port access laparoscopic for adnexal pathology

Conditions: Adnexal Benign Pathology

Summary: during laparoscopy pneumoperitoneum creates the necessary space in which to perform the operation. growing evidence in general surgery has shown that reduction of intra-abdominal pressure during laparoscopy is related to improved postoperative outcomes, decreased pain perception, length of hospital stay, and analgesic rescue dosage in patients undergoing minimally invasive procedures using low pneumoperitoneum pressure (lpp) compared with standard pneumoperitoneum pressure (spp). aim of the study is to demonstrate the safety and feasibility of lpp during performance of single port access laparoscopy for benign adnexal pathologies.


Eligibility criteria:
inclusion criteria: * patients 18- 45 years old * elective laparoscopic operation * informed consent exclusion criteria: * bmi \> 30 kg/cm2 * pregnancy * converting to laparotomy * malignant disease * unable or unwilling to give written consent
immunogenicity & reactogenicity of various formulations of recombinant hepatitis b vaccine with different adjuvants

Conditions: Hepatitis B

Summary: the purpose of this study is to evaluate the immunogenicity and reactogenicity of various formulations of recombinant hepatitis b vaccine with different adjuvants in healthy adult volunteers following the 0, 1, 6 months schedule

at the time of conduct of this study, the sponsor glaxosmithkline was known by its former name smithkline beecham

Eligibility criteria:
inclusion criteria: * between 18 and 40 years old. * written informed consent will have been obtained from the subjects. * good physical condition as established by physical examination and history taking at the time of entry. * female participants will avoid becoming pregnant during the study period and they will have been on a contraceptive program for at least 2 months before entry exclusion criteria: * pregnancy or lactation. * serological signs of hbv infection * elevated serum liver enzymes * any vaccination against hepatitis b in the past. * any previous administration of mpl. * history of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease. * axillary temperature \> 37.5°c at the time of injection. * any acute disease at the moment of entry. * chronic alcohol consumption. * any treatment with immunosuppressive or immunostimulant therapy. * any chronic drug treatment, which in the investigator's opinion, precludes inclusion into the study. * history of allergic disease likely to be stimulated by any component of the vaccine. * administration of any other vaccine(s) or any immunoglobulin during the study period. * simultaneous participation in any other clinical trial.

Keywords: hepatitis b engerix™-b recombinant hepatitis b vaccine
the longevity of trichuris trichiura colonization

Conditions: Helminthiasis; Helminth Infection

Summary: the aim of the study was to study the longevity of trichuris trichiura colonization

the present study investigates the longevity of trichuris trichiura colonization in a human volunteer as measured by regular fecal sampling.

Eligibility criteria:
inclusion criteria: the included volunteer is a researcher within parasitology with focus on trichuris trichiura and trichiura suis. he planned to infect himself under medical supervision. this was his third self-infection with trichuris. the only clinical criterion for his inclusion in the study was that he was healthy. exclusion criteria: n/a
effect of male circumcision on hiv incidence (anrs 1265)

Conditions: HIV Infections; Herpes Genitalis; Venereal Diseases

Summary: observational studies suggest that male circumcision may provide protection against hiv-1 infection. a randomized, controlled, intervention trial was conducted in a general population of south africa to test this hypothesis.

this study is a randomized controlled intervention trial. this multi-centre study will take place in 3 centers located around johannesburg, in the areas of orange farm, sebokeng and evaton. the intervention group patients (circumcised at the beginning of the trial) and the control group (uncircumcised men) will be followed during 21 months (from m.0 to m. 21). randomization and medicalized circumcision will be performed at m.0 in the intervention group and might be optional in the control group at end of study. the medicalized circumcision effectiveness will be evaluated on and after m.3 (3 months after medicalized circumcision). incidences (of hiv, hsv-2 infections and genital ulcer disease) will be compared from m.3 to m.21 between the intervention group and the control group. an intermediate analysis will take place at m. 12.

Eligibility criteria:
inclusion criteria: * uncircumcised men aged 18-24 years * be in good general condition with normal physical and genital examinations * consenting to participate in the trial and to sign an informed consent * consenting to randomization of the medicalized circumcision schedule (performed at the beginning of study for the treated group, optional at the end of study for the control group) * consenting to avoid sexual contact (except with condom protection) during the 6 weeks following the medicalized circumcision * consenting to blood tests at m.0, m.3, m.12 and m.21 tested for hiv, hsv-2 and syphilis. exclusion criteria: * men with aids * men with contraindication for circumcision * men thinking of moving away from the trial sites within the 21 months following inclusion * men with clinical sexually transmitted diseases (stds) (those men could be included after treatment)

Keywords: hiv male circumcision prevention hsv-2 africa sexual behavior
expression of parp-1 in multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: this study will explore the expression of parp-1 in optic neuritis of multiple sclerosis patients. the data will be collected from sohag university hospital in the period from the start of august 2021 to the end of december 2021. the study protocol will be approved by the scientific research ethical committee, faculty of medicine, sohag university.


Eligibility criteria:
inclusion criteria: * patients with multiple sclerosis with or without optic neuritis multiple sclerosis will be diagnosed according to the mcdonald criteria exclusion criteria: * • isolated optic neuritis.

Keywords: optic neuritis-multiple sclerosis-parp-1
controlled trial of 3,4-diaminopyridine (3-4dap) in lambert-eaton myasthenic syndrome (lems)

Conditions: Muscle Weakness

Summary: the main purpose for this study is to provide access to 3,4 dap, a drug which has demonstrated to be effective in treating weakness associated with lambert-eaton myasthenic syndrome. lems is a rare autoimmune cause of a defect in neuromuscular transmission. the disorder is clinically characterized by fluctuating muscle weakness, hyporeflexia and autonomic dysfunction.

more than half of lems cases are associated with malignancy, usually small cell lung cancer. these paraneoplastic cases progress more quickly than primary autoimmune lems. an overlap syndrome with other autoimmune diseases is often detected in lems patients. 3,4 dap is effective in lems because it increases calcium influx into the nerve terminal by blocking potassium efflux and thereby prolonging the presynaptic action potential. 3,4 dap is less likely to provoke epileptic seizures than its precursor, 4-aminopyridine, because it is less able to cross the blood-brain barrier. 3,4 dap is effective in increasing strength and improving autonomic symptoms in lems patients of both the primary autoimmune and paraneoplastic etiologies.

Eligibility criteria:
inclusion criteria: -male or female majority between 45 and 60 years of age * diagnosed with lambert-eaton myasthenic syndrome. * subjects must be taking full dose of pyridostigmine exclusion criteria: - does subject have a history of liver problems? * does subject have a history of prolonged qtc syndrome (which is a condition where there is prolongation between the start of the q wave and the end of the t wave in the heart's electrical cycle).

Keywords: fluctuating muscle weakness hyporeflexia autonomic dysfunction
effectiveness of tai chi exercise program in scleroderma patients

Conditions: Tai Chi

Summary: because of multiple system involvement, patients with scleroderma have complaints such as fatigue, sleep disturbances, functional limitations, skin deformations, pain, swollen hands and joint pain. the aim of this study is to investigate the effect of tai chi exercise program on trunk endurance, balance, sleep, fatigue, anxiety and depression in patients with scleroderma.

in the study, which will be planned as a randomized controlled parallel group, the effects of tai chi in ss patients are compared with the home exercise group. evaluations before and after the treatment will make by a physiotherapist. training of tai chi will supervised by an experienced and certified physiotherapist. lateral bridge test , berg balance scale, pittsburg sleep quality index , fatigue severity scale and fatigue impact scale , hospital anxiety and depression scale will be used evaluation before and after training.

Eligibility criteria:
inclusion criteria: * have been diagnosed with scleroderma, * have been sedentary (have not routinely participated in exercise activities during the past 3 months) * have been using a fixed dose of medication for at least 6 months * no communication problems * having stable disease exclusion criteria: * a diagnosis of pulmonary hypertension * a history of active infection, cardiac involvement, psychiatric disorder, a history of active myositis, renal failure, metastatic cancer, pregnancy * data of the participant whose changes were made during the study are not included in this study and participation is terminated.

Keywords: scleroderma tai chi sleep fatique depression anxiety
acceptability of a fixed combination of fenofibrate and metformin

Conditions: Dyslipidemia/Glucose Metabolism Disorder

Summary: the primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia.


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes mellitus and dyslipidemia. exclusion criteria: * type 1 diabetes, uncontrolled type 2 diabetes, - hba1c ≥ 10 % - fasting plasma glucose \> 300 mg/dl - triglycerides \> 500 mg/dl

Keywords: treatment of dyslipidemia and of type 2 diabetes mellitus
evaluation of serum interleukin 6 and 8 in children with acute gastroenteritis

Conditions: Acute Gastroenteritis; Acute Diarrhea

Summary: cytokines, such as il-6 and il-8 can be used as markers of acute infections, including acute gastroenteritis. this study aims to evaluate serum levels of interleukins 6 and 8 in children with acute gastroenteritis.


Eligibility criteria:
group 1: cases (children with acute diarrhea) inclusion criteria: * children aged 6 months to 5 years. * acute diarrhea: defined according to who criteria as the "passage of loose or watery stools at least three times in a 24 h period", lasts less than 14 days, with or without fever or vomiting, but considering the importance of change in stool consistency rather than frequency, and the usefulness of parental insight in deciding whether children have diarrhea or not. exclusion criteria: * malnutrition or obesity * history of antibiotic therapy in the last 72 hours. * acute diarrhea in association with systemic infections * malignancy * chronic diarrhea * autoimmune and autoinflammatory diseases. * chronic renal/liver failure * diabetes mellitus group 2: controls (healthy control children) inclusion criteria: • healthy children aged 6 months to 5 years. exclusion criteria: * acute diarrhea * malnutrition or obesity * history of antibiotic therapy in the last 72 hours. * acute diarrhea in association with systemic infections * malignancy * chronic diarrhea * autoimmune and autoinflammatory diseases. * chronic renal/liver failure * diabetes mellitus